Skip to main content

Table 1 Antimicrobial susceptibility test and molecular results for all ceftazidime-resistant P. aeruginosa isolates (n = 26) responsible of bloodstream infections (BSI)

From: Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase

Isolates

MIC of agents (μg/ml) a

Type of enzymes produced

 

PIP

TZP

CAZ

FEP

ATM

IMP

MEM

CIP

AMK

GEN

 

338/98

> 256

> 256

> 256

128

> 256

8

32

> 32

64

> 256

AmpC, PER-1

LS034/99

> 256

> 256

> 256

> 256

> 256

> 32

> 32

> 32

64

> 256

AmpC, PER-1

140/99

> 256

> 256

> 256

64

> 256

16

32

> 32

64

> 256

AmpC, PER-1

47/00

> 256

> 256

> 256

128

> 256

16

8

> 32

16

> 256

AmpC, PER-1

324/00

> 256

> 256

> 256

> 256

> 256

> 32

16

> 32

16

> 256

AmpC, PER-1

A360/00

> 256

> 256

> 256

> 256

> 256

> 32

16

> 32

16

> 256

AmpC, PER-1

527/00

> 256

> 256

> 256

> 256

> 256

> 32

32

> 32

16

> 256

AmpC, PER-1

2126/01

> 256

> 256

> 256

64

> 256

16

8

> 32

32

> 256

AmpC, PER-1

A150/02

> 256

> 256

> 256

48

> 256

> 32

32

> 32

> 256

> 256

AmpC, PER-1

299/98

> 256

128

32

64

32

2

2

0.094

4

8

AmpC

77/99

> 256

64

64

16

64

4

2

0.5

8

8

AmpC

251/00

> 256

128

16

32

16

2

4

> 32

128

> 256

AmpC

746/00

> 256

64

16

64

16

8

8

> 32

96

> 256

AmpC

2497/01

> 256

128

16

128

16

2

1

0.125

8

> 256

AmpC

2544/01

256

64

32

128

64

16

2

0.5

16

> 256

AmpC

A372/02

64

32

16

32

32

0.5

0.5

> 32

32

> 256

AmpC

A480/02

> 256

64

64

16

8

> 32

16

0.094

1

4

AmpC

659/02

96

32

32

16

16

1

0.5

> 32

8

> 256

AmpC

694/02

128

64

16

8

16

4

8

> 32

16

> 256

AmpC

A276/03b

64

32

32

16

16

1

0.5

> 32

16

> 256

AmpC

A562/03b

64

16

32

16

16

1

0.5

> 32

16

> 256

AmpC

A173/03b

32

4

32

16

16

1

0.5

> 32

4

8

AmpC

A189/03 c

32

16

32

16

8

1

0.5

> 32

8

> 256

AmpC

A590/03

> 256

128

64

8

64

32

8

0.125

0.5

2

AmpC

A424/04

> 256

64

64

4

32

4

2

0.094

1

4

AmpC

A567/04 c

128

64

64

16

16

1

0.5

0.125

0.5

2

AmpC

  1. a MIC values were obtained using the Etest method (AB Biodisk). Abbreviations of antimicrobial agents and breakpoints for susceptibility (S) and resistance (R) are given: PIP, piperacillin (S ≤ 64, R ≥ 128); TZP, piperacillin plus tazobactam (S ≤ 64, R ≥ 128); CAZ, ceftazidime (S ≤ 8, R ≥ 32); FEP, cefepime (S ≤ 8, R ≥ 32); ATM, aztreonam (S ≤ 8, R ≥ 32); IPM, imipenem (S ≤ 4, R ≥ 16); MEM, meropenem (S ≤ 4, R ≥ 16); CIP, ciprofloxacin (S ≤ 1, R ≥ 4); AMK, amikacin (S ≤ 16, R ≥ 64); GEN, gentamicin (S ≤ 4, R ≥ 16).
  2. b These strains caused three different BSI in the same patient.
  3. c Only microbiological data were available. Therefore, these 2 cases were excluded from statistical analysis of demographic data, risk factors and treatment outcome.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us